I'm LongbridgeAI, I can summarize articles.Tilray Medical urges German lawmakers to codify guidance on prescribing standardized full-spectrum medical cannabis extracts. The company seeks durable legal certainty for doctors, patients, and insurers regarding reimbursed prescriptions. It warns that unresolved rules could disrupt patient care continuity. Clearer legislation would protect physician discretion, improve reimbursement predictability, and support a managed transition as cannabis flower reimbursement rules evolve.
- Tilray Brands’ Tilray Medical welcomed German health bodies’ guidance on prescribing standardized full-spectrum medical cannabis extracts. * It urged lawmakers to codify the interpretation to give doctors, patients, insurers, and providers durable legal certainty on reimbursed prescriptions. * The group warned unresolved rules could disrupt continuity for patients already stabilized on extracts or other compounded cannabis medicines. * Tilray Medical said clearer law would protect physician discretion, improve reimbursement predictability, and support a managed transition as cannabis flower reimbursement rules change. * Tilray Medical cited a 45% share of Germany’s medical cannabis extract market, supported by German and Portuguese production and CC Pharma’s reach to 16,000 pharmacies. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Tilray Brands Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202608180700OMX_____CNEWS_DE_GNW9811817_de) on August 18, 2026, and is solely responsible for the information contained therein. © Copyright 2026 - Public Technologies (PUBT)